Many Spinal Manipulation Trials Don't Report Adverse Events

This article originally appeared here.
Share this content:
Many Spinal Manipulation Trials Don't Report Adverse Events
Many Spinal Manipulation Trials Don't Report Adverse Events

TUESDAY, Sept. 27, 2016 (HealthDay News) -- Many randomized clinical trials (RCTs) involving spinal manipulative therapy (SMT) do not report adverse events, although there has been an increase in such reporting since publication of the 2010 Consolidated Standards of Reporting Trials (CONSORT) statement, according to a review published in the September issue of The Spine Journal.

Lindsay M. Gorrell, B.Chiro.Sc., M.Chiroprac., from Macquarie University in Sydney, and colleagues conducted a systematic literature review to describe the extent of adverse event reporting in published RCTs involving SMT. A total of 368 articles were eligible for inclusion in the review. The differences in the proportions between pre- and post-CONSORT trials were calculated.

The researchers found that there were reports of adverse events in 38.0 percent of the articles. Post-CONSORT, there was a significant increase in the reporting of adverse events (P = 0.001). Only two major adverse events were reported (0.3 percent). Adverse events were reported in the abstract in 22 articles (15.7 percent). For the chosen parameters, there were no differences in reporting of adverse events post-CONSORT.

"Although there has been an increase in reporting adverse events since the introduction of the 2010 CONSORT guidelines, the current level should be seen as inadequate and unacceptable," the authors write. "We recommend that authors adhere to the CONSORT statement when reporting adverse events associated with RCTs that involve SMT."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »